Member Info for Chazzy2

Yes, a very encouraging update. FFWD own 2.11% which ok doesn't sound alot but cancer immunotherapy companies get bought for billions, and Intensity's in vivo approach to treating cancer using cell penetration enhancers is quite unique. If you like Intensity SALV own 8.5%, for a bigger slice of the cake!

http://intensitytherapeutics.com/intensity-therapeutics-inc-announces-presentation-int230-6-clinical-study-2018-asco-conference/ All sounds encouraging.

http://intensitytherapeutics.com/intensity-therapeutics-inc-announces-presentation-int230-6-clinical-study-2018-asco-conference/ ''To date no dose limiting toxicities following treatments to 14 patients having nine different solid tumour types.'' All sounds very encouraging.

Can you post the statement please Mat? Not sure which one you are referring to. Cheers

https://seekingalpha.com/article/4178775-aphria-inc-question-patience

Whilst it's encouraging news for the early detection of cancer the technology of examining ctDNA as a biomarker for cancer is nothing new and is still in the very early stages of development. Angle's system is not only far superior because of Parsortix's ability to capture living cells, but is also streets ahead in development terms because of the clinical trials already underway and with FDA approval a few months away if all goes well. What the article does highlight is the importance of liquid biopsy as a simple and cost effective alternative to solid biopsies in the future.

I understood the servers receive factoid tokens which increase in price based on demand, and these get converted to ECs, but companies can also receive ECs directly to avoid getting involved in cryptocurrency. Wouldn't the proceeds of the sale of ECs in that instant go to Factom Inc. Or is it the case that Factom Inc. Only generates money from software and subscriptions?

Does anyone know how Factom inc. actually generates revenue. From what I have been able to ascertain from Reddit companies wishing to secure data using the factom protocol buy entry credits for 0.1 of a cent, allowing the storage of 1KB of data per EC. Does this money then go to Factom inc. and is that therefore their main source of revenue? Others on Reddit have suggested that Factom Inc. revenue stream will come from software sales and subscriptions. Any ideas?

Just some of the industries and locations where the Factom servers will be located. Gives an indication of the breath of the rollout. https://factomize.com/introducing-the-first-21-factom-protocol-authority-nodes/

Just one more post from me today! This link is one of the most informative posts I've seen about Factom and its business model, even if it is a few months old now. Reddit seems to be a really good source of information with some very good comments. https://www.reddit.com/r/factom/comments/7rg5po/factom_fct_has_cornered_the_market_in_data/

Yooya is the real dark horse in the portfolio. Just no information whatsoever, via twitter or anywhere. I'd just love to have an inkling as to its progress, sales figures, profit, just to get an idea of possible current value. We know 15 months ago it was receiving 3 billion views per month but how that translates into hard cash is anyone's guess.

Yes it's gone very quiet on several fronts. I'm pleased in a way about the delay in the sale of Leap as the recent legalisation of sports gambling in the US should boost its value long term, so its probably worth hanging on to it a bit longer. Would love to hear some news about Yooya also. And also factom and the long awaited news of actual confirmed clients of course.

LS, I'm referring to the possible market cap of Aphria if and when it reaches its production target of 240,000 kg of product in 12 months or so. 5x its current market cap is not inconceivable.

https://www.newswire.ca/news-releases/aphria-inc---revenue-growth-and-sub-100-cash-cost-per-gram-metric-highlight-quarter-679851353.html In Q3 2018 Aphria sold 1428 kg cannabis product resulting in EBITDA of CAD 2,940. Suggests at this rate when producing to intended capacity of 240,000 kg in 12 months EBIDTA should be in the region of CAD 500,000. Add conservative P/E of 25 and you have market cap of CAD 12.5 billion or 5 times current market cap. Factoring in economy of scaling up and this figure could be higher of course. Any comments?

up 7.6%. All adds nicely to our NPV.

https://www.reddit.com/r/factom/comments/7rg5po/factom_fct_has_cornered_the_market_in_data/

Wow, fascinating link Robrob. So much to digest but it really gives you an idea of the scale and opportunity for Factom.

Wow, fascinating link Robrob. So much to digest but it really gives you an idea of the scale and opportunity for Factom.

The potential for Lupuzor is massive and there is no reason why another phase 3 trial for Lupus could not be conducted under different refined parameters to increase its chances of a successful outcome next time. Also knowing its excellent safety profile will mean that any future trials in other autoimmune indications will most probably start at phase 3 level. Plenty to play for, and very much a target still for a big pharma to acquire.

Yes great news. It's a real endorsement of Intensity's future for such a high profile person who was president and COO of Parexel to join the board. That speaks volumes. Salvarx is really under the radar right now but release of clinical data will change all that. If like me Wadders you are in SALV and FFWD it will be a double bonus one day!